Cargando…

Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib

EGFR-TKIs show dramatic treatment benefits for advanced lung adenocarcinoma patients with activating EGFR mutations. Considering the essential role of autophagy in EGFR-TKIs treatments, we hypothesized that genetic variants in autophagy core genes might contribute to outcomes of advanced lung adenoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Jupeng, Zhang, Nasha, Yin, Longbin, Zhu, Hui, Zhang, Li, Zhou, Liqing, Yang, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736620/ https://www.ncbi.nlm.nih.gov/pubmed/29259263 http://dx.doi.org/10.1038/s41598-017-18165-5

Ejemplares similares

Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
por: Liu, Chien-Ming, et al.
Publicado: (2015)

Starvation-induced suppression of DAZAP1 by miR-10b integrates splicing control into TSC2-regulated oncogenic autophagy in esophageal squamous cell carcinoma
por: Chen, Yunsong, et al.
Publicado: (2020)

Influence of Autophagy Inhibition on Lung Adenocarcinoma Cell Migration and Invasion Ability, and Efficacy of Gefitinib
por: Liu, Ying, et al.
Publicado: (2021)

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
por: Gozzi, Fabrizio, et al.
Publicado: (2021)

Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
por: Liu, Yu-Tao, et al.
Publicado: (2015)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
por: Yu, Ruofei, et al.
Publicado: (2021)

Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases
por: Ryu, Yon Ju, et al.
Publicado: (2014)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
por: WANG, ZHUN, et al.
Publicado: (2015)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
por: Yang, Hong, et al.
Publicado: (2021)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Hinokitiol Induces DNA Damage and Autophagy followed by Cell Cycle Arrest and Senescence in Gefitinib-Resistant Lung Adenocarcinoma Cells
por: Li, Lan-Hui, et al.
Publicado: (2014)

Perforating Corneal Ulceration in a Patient with Lung Metastatic Adenocarcinoma Treated with Gefitinib: A Case Report
por: Ibrahim, Enjie, et al.
Publicado: (2012)

Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients
por: Sugiura, Yasoo, et al.
Publicado: (2013)

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
por: Bria, Emilio, et al.
Publicado: (2015)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Plasmodium Circumsporozoite Protein Enhances the Efficacy of Gefitinib in Lung Adenocarcinoma Cells by Inhibiting Autophagy via Proteasomal Degradation of LC3B
por: Lu, Xiao, et al.
Publicado: (2022)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

CHST9 rs1436904 genetic variant contributes to prognosis of triple-negative breast cancer
por: Yuan, Jupeng, et al.
Publicado: (2017)

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer: HMGB1-mediated autophagy promotes gefitinib resistance
por: Lei, Tianyao, et al.
Publicado: (2022)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Identification of Key Genes and Pathways in Gefitinib-Resistant Lung Adenocarcinoma using Bioinformatics Analysis
por: Mao, Kailin, et al.
Publicado: (2021)

Orbital metastasis secondary to pulmonary adenocarcinoma treated with gefitinib: a case report
por: Koma, Yasuko, et al.
Publicado: (2012)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

miR-1262 suppresses gastric cardia adenocarcinoma via targeting oncogene ULK1
por: Zheng, Yan, et al.
Publicado: (2021)

Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma
por: Lee, Joo Young, et al.
Publicado: (2012)

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015)

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
por: He, Jian, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
por: Ni, Jie, et al.
Publicado: (2018)

Gefitinib Treatment Was Unsuccessful for Central Diabetes Insipidus Due to Pituitary Metastasis of Lung Adenocarcinoma
por: Tanaka, Shunnosuke, et al.
Publicado: (2020)

Comprehensive Analysis of Circular RNA Expression Profiles in Gefitinib-Resistant Lung Adenocarcinoma Patients
por: Zou, Junyong, et al.
Publicado: (2022)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
por: Bersanelli, Melissa, et al.
Publicado: (2014)

High efficacy of gefitinib in the treatment of EGFR mutation-positive advanced non-small cell lung adenocarcinoma: A case report
por: WANG, ZHONGCHAO, et al.
Publicado: (2014)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy
por: Li, Xiao-Qiu, et al.
Publicado: (2016)

Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations
por: Liu, Ning, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_51urnia1n5sk91tionm3iegcig